Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
CA 3144557
LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS
granted -
WO 2021001362
LIGANDS D'ANTIGÈNE MEMBRANAIRE SPÉCIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS
granted -
US 10889637
Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
granted -
US 10888565
Compounds and compositions for ossification and methods related thereto
granted -
US 10888617
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
granted -
US 10889556
Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease
granted -
US 10889834
Methods and compositions for enhancing targeted transgene integration
granted -
US 10888578
Exon skipping oligomer conjugates for muscular dystrophy
granted -
US 10888597
Composition for treating brain stroke
granted -
US 10889576
Phthalazinone compounds and methods for the treatment of cystic fibrosis
granted -
US 10888618
Method of treating cancer
granted -
US 10888619
Stable aqueous etanercept composition
granted -
US 10889543
Fine-tune modulators of neuronal excitability for neuropsychiatric disorders
granted -
US 10889813
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
granted -
US 10888529
Vehicles for the transfection of miRNAs
granted -
US 10888558
Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
granted -
US 10888601
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 10889592
Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
granted -
US 10889577
Solid forms of an sGC stimulator
granted -
US 10889580
Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
granted -
US 10889587
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
granted -
US 10889607
Sialic acid analogs
granted -
US 10889817
Oligonucleotide therapy for Leber Congenital Amaurosis
granted -
US 10889538
Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same
granted -
US 10888517
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 10889562
Prodrugs of Nrf2 activating compounds and uses thereof
granted -
US 10888499
Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
granted -
US 10888581
Chimeric antigen receptor and methods of use thereof
granted -
US 10889625
Peptide-based methods for treating neurological injury
granted -
US 10888516
Soluble estradiol capsule for vaginal insertion
granted -
US 10888609
CD200 inhibitors and methods of use thereof
granted -
US 10888589
Modulation of stem cells using zinc finger proteins
granted -
US 10889561
Process of making somatostatin modulators
granted -
US 10888554
Salts of heterocyclic modulators of HIF activity for treatment of disease
granted -
WO 2021005497
ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIUM POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À LA DÉPRESSION CORTICALE ENVAHISSANTE
granted -
WO 2021005493
ANTAGONISTES DU CGRP ET TOXINES BOTULINIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET NEUROLOGIQUES
granted -
WO 2021005494
ANTAGONISTES DU CGRP ET DÉRIVÉS DE CLOSTRIDIALES POUR LE TRAITEMENT DE TROUBLES NEUROPSYCHIATRIQUES ET NEUROLOGIQUES
granted -
US 10894061
Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
granted -
US 10894007
Hair care composition with encapsulated moisturizers and method to deliver extended moisture release to the hair
granted -
US 10894077
Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA)
granted -
US 10894053
Pharmaceutical compositions comprising meloxicam
granted -
US 10894044
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
granted -
US 10894786
Substituted pyrazole derivatives as selective CDK12/13 inhibitors
granted -
US 10894816
Use of IL-15 to increase thymic output and to treat lymphopenia
granted -
US 10894033
Multicyclic compounds and methods of use thereof
granted -
US 10894034
Anti-neoplastic compounds and methods targeting QSOX1
granted -
US 10894087
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
granted -
US 10894050
Methods of synthesizing thyroid hormone analogs and polymorphs thereof
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.